Tetraspanin CD9 Limits Mucosal Healing in Experimental Colitis

Area of Science:

• Immunology
• Cell Biology
• Gastroenterology

Background:

• Tetraspanins, including CD9, form microdomains regulating cellular processes.
• CD9 influences leukocyte interactions and immune responses, but its in vivo role in inflammatory diseases like inflammatory bowel disease (IBD) is unclear.
• Existing research highlights CD9's in vitro role in leukocyte-endothelium interactions.

Purpose of the Study:

• To investigate the in vivo role of CD9 in the pathogenesis of colitis, a model for IBD.
• To determine whether CD9's function in colitis is mediated by hematopoietic or non-hematopoietic cells.

Main Methods:

• Induction of colitis in CD9 knockout (CD9^-/-) and wild-type mice using dextran sodium sulfate (DSS).
• Analysis of immune cell infiltration, cytokine levels, and survival rates.
• Transfer of naive T cells and bone marrow chimera experiments to differentiate CD9's role in hematopoietic versus non-hematopoietic compartments.

Main Results:

• CD9^-/- mice exhibited significantly reduced colitis severity and increased survival following DSS administration compared to wild-type mice.
• Reduced neutrophil and macrophage infiltration, along with lower pro-inflammatory cytokine levels (TNF-α, IL-6), were observed in CD9^-/- mice.
• CD9 in non-hematopoietic cells, not hematopoietic cells, was found to be critical for colon injury and limiting epithelial cell proliferation.

Conclusions:

• CD9 plays a significant role in the pathogenesis of colitis, primarily through its action in non-hematopoietic cells.
• CD9 in non-hematopoietic cells limits epithelial cell proliferation, contributing to colon injury during inflammation.
• Targeting CD9 expression could represent a novel therapeutic strategy for treating inflammatory bowel disease.